Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Docetaxel/Prednisone With or Without Custirsen in Metastatic Castration-Resistant Prostate Cancer
DRKS00003891Phase 3Completed
- Sponsor
- Teva Pharmaceutical Industries Ltd.
- Start
- Apr 2012
- Modality
- Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 12
01
Overview
Phase 3, randomised trial of custirsen in prostate cancer (PCa) (2 arms), sponsored by Teva Pharmaceutical Industries Ltd. Started Apr 2012; status: completed.
02
Drugs
custirsen
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on DRKS00003891.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on DRKS00003891.